McKesson Co. (MCK) Shares Bought by Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. boosted its holdings in McKesson Co. (NYSE:MCK) by 46.2% in the third quarter, HoldingsChannel reports. The firm owned 2,357 shares of the company’s stock after buying an additional 745 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in McKesson were worth $313,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Fort L.P. acquired a new stake in shares of McKesson in the second quarter valued at approximately $110,000. Flagship Harbor Advisors LLC acquired a new stake in shares of McKesson in the second quarter valued at approximately $118,000. Reilly Financial Advisors LLC boosted its holdings in shares of McKesson by 506.8% in the third quarter. Reilly Financial Advisors LLC now owns 898 shares of the company’s stock valued at $119,000 after acquiring an additional 750 shares during the period. Squar Milner Financial Services LLC acquired a new stake in shares of McKesson in the second quarter valued at approximately $179,000. Finally, Sun Life Financial INC boosted its holdings in shares of McKesson by 450.6% in the second quarter. Sun Life Financial INC now owns 1,349 shares of the company’s stock valued at $180,000 after acquiring an additional 1,104 shares during the period. 89.19% of the stock is owned by hedge funds and other institutional investors.
MCK has been the subject of several research analyst reports. ValuEngine raised McKesson from a “strong sell” rating to a “sell” rating in a report on Monday, October 29th. Mizuho restated a “hold” rating and set a $133.00 price target on shares of McKesson in a research note on Sunday, August 12th. Royal Bank of Canada set a $155.00 price target on McKesson and gave the stock a “hold” rating in a research note on Friday, October 26th. Jefferies Financial Group restated a “buy” rating and set a $160.00 price target on shares of McKesson in a research note on Friday, July 27th. Finally, Citigroup cut their price target on McKesson from $160.00 to $2.86 and set a “buy” rating for the company in a research note on Friday, July 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $150.26.
McKesson (NYSE:MCK) last released its quarterly earnings results on Thursday, October 25th. The company reported $3.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.28 by $0.32. The business had revenue of $53.08 billion during the quarter, compared to analysts’ expectations of $53.56 billion. McKesson had a return on equity of 26.55% and a net margin of 0.06%. As a group, sell-side analysts anticipate that McKesson Co. will post 13.41 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 2nd. Shareholders of record on Monday, December 3rd will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 1.19%. The ex-dividend date is Friday, November 30th. McKesson’s payout ratio is 12.36%.
In other McKesson news, Director N Anthony Coles sold 1,350 shares of the stock in a transaction on Friday, August 31st. The stock was sold at an average price of $128.69, for a total value of $173,731.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.87% of the company’s stock.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Read More: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.